KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

ABSTRACT:

Background

Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants actually resemble metastasis owning the same genetic pattern as the ovarian primary or whether they develop independently.

Methods

The current study, in the aim of further clarifying the genetic origin of implants, assessed BRAF/KRAS hot spot mutations and the p53/p16INK4a immunophenotype of s-BOTs and corresponding implants (n=49) of 15 patients by pyro-sequencing and immunostaining, respectively.

Results

A significant proportion of bo

SUBMITTER: Heublein S 

PROVIDER: S-EPMC4015926 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature